Recent Finacing
Recent Raise
OMEICOS Therapeutics develops orally available synthetic analogues of omega‑3–derived epoxyeicosanoids (lead OMT‑28) for atrial fibrillation, cardiovascular, inflammatory and ophthalmic indications, currently in Phase 1/2 clinical studies.
